From hit to vial: Precision discovery and development of an imidazopyrimidine TLR7/8 agonist adjuvant formulation
Science Advances · 2024
DOI: 10.1126/sciadv.adg3747 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2024. Verfasst von Dheeraj Soni und 25 weiteren Autor:innen. Beteiligte Einrichtung: Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA. Hauptthemen laut MEDLINE: Toll-Like Receptor 8, Adjuvants, Immunologic, Toll-Like Receptor 7, Pyrimidines. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
Vaccination can help prevent infection and can also be used to treat cancer, allergy, and potentially even drug overdose. Adjuvants enhance vaccine responses, but currently, the path to their advancement and development is incremental. We used a phenotypic small-molecule screen using THP-1 cells to identify nuclear factor-κB (NF-κB)–activating molecules followed by counterscreening lead target libraries with a quantitative tumor necrosis factor immunoassay using primary human peripheral blood mononuclear cells. Screening on primary cells identified an imidazopyrimidine, dubbed PVP-037. Moreover, while PVP-037 did not overtly activate THP-1 cells, it demonstrated broad innate immune activation, including NF-κB and cytokine induction from primary human leukocytes in vitro as well as enhancement of influenza and SARS-CoV-2 antigen-specific humoral responses in mice. Several de novo synthesis structural enhancements iteratively improved PVP-037’s in vitro efficacy, potency, species-specific activity, and in vivo adjuvanticity. Overall, we identified imidazopyrimidine Toll-like receptor-7/8 adjuvants that act in synergy with oil-in-water emulsion to enhance immune responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA.
- Harvard Medical School, Boston, MA, USA.
- Dana-Farber Cancer Institute, Boston, MA, USA.
- Department of Molecular Medicine, The Scripps Research Institute, Jupiter, FL, USA.
- Access to Advanced Health Institute (AAHI), Seattle, WA, USA.
- Pritzker School of Molecular Engineering, University of Chicago, Chicago, IL, USA.
ORCID-Profile: Dheeraj Soni, David A Scott, Frederic Feru, Maria DeLeon, Spencer E Brightman, Jennifer A Smith, Soumik Barman, Michael Cameron, Aisling Kelly, Etsuro Nanishi, Simon Daniel van Haren, Michal M Raczy, Al Ozonoff, Matthew A Pettengill, Jeffery A Hubbell, Christopher B Fox, David J Dowling, Ofer Levy
Förderung
- NIAID NIH HHS
Zitieren
APA
Soni, D., Borriello, F., Scott, D. A., Feru, F., DeLeon, M., Brightman, S. E., Cheng, W. K., Melhem, G., Smith, J. A., Ramirez, J. C., Barman, S., Cameron, M., Kelly, A., Walker, K., Nanishi, E., van Haren, S. D., Phan, T., Qi, Y., Kinsey, R., …, & Levy, O. (2024). From hit to vial: Precision discovery and development of an imidazopyrimidine TLR7/8 agonist adjuvant formulation. Science Advances. https://doi.org/10.1126/sciadv.adg3747
Vancouver
Soni D, Borriello F, Scott DA, Feru F, DeLeon M, Brightman SE, et al. From hit to vial: Precision discovery and development of an imidazopyrimidine TLR7/8 agonist adjuvant formulation. Science Advances. 2024. doi:10.1126/sciadv.adg3747
BibTeX
@article{Soni2024,
author = {Soni, Dheeraj and Borriello, Francesco and Scott, David A and Feru, Frederic and DeLeon, Maria and Brightman, Spencer E and Cheng, Wing Ki and Melhem, Gandolina and Smith, Jennifer A and Ramirez, Juan C and Barman, Soumik and Cameron, Michael and Kelly, Aisling and Walker, Kristina and Nanishi, Etsuro and van Haren, Simon Daniel and Phan, Tony and Qi, Yizhi and Kinsey, Robert and Raczy, Michal M and Ozonoff, Al and Pettengill, Matthew A and Hubbell, Jeffery A and Fox, Christopher B and Dowling, David J and Levy, Ofer},
title = {From hit to vial: Precision discovery and development of an imidazopyrimidine TLR7/8 agonist adjuvant formulation},
journal = {Science Advances},
year = {2024},
doi = {10.1126/sciadv.adg3747}
}
EUVIMED